Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pandemic H5N1 Influenza Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

NCT01310413
View directory record Official record
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus monovalent vaccine, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
11
States / cities
Paramount, California • Sacramento, California • Newton, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

NCT01766921
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
1,393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Phoenix, Arizona • Hollywood, Florida • Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019
View directory record Official record
Conditions
Influenza
Interventions
Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years to 40 Years
Enrollment
753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

NCT01995695
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00719043
View directory record Official record
Conditions
Influenza
Interventions
A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

NCT00519389
View directory record Official record
Conditions
Pandemic Influenza
Interventions
H5N1 VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT00664417
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

NCT01776541
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 64 Years
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle)

NCT00709800
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPT1, VCL-IPM1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

NCT02274545
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

NCT06382311
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Influenza virus vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
991 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
21
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

NCT07496450
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1018-H5, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
10
States / cities
San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

NCT00922259
View directory record Official record
Conditions
Influenza A
Interventions
Influenza A H7N7 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jul 23, 2026, 10:56 AM EDT